Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage I Prostate Adenocarcinoma Clear all
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002703
View directory record Official record
Conditions
Prostate Cancer
Interventions
high-LET heavy ion therapy, low-LET photon therapy
Radiation
Lead sponsor
Proton Radiation Oncology Group
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Loma Linda, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jul 23, 2026, 6:32 PM EDT
Not listed Phase 1Phase 2 Interventional

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

NCT00003183
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 23, 2026, 6:32 PM EDT
Terminated Not applicable Interventional Results available

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer

NCT02454517
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
Interventions
Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 23, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970
View directory record Official record
Conditions
Prostate Cancer
Interventions
celecoxib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 23, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

NCT01480154
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Hydroxychloroquine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 6:32 PM EDT
Terminated No phase listed Observational

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

NCT00379119
View directory record Official record
Conditions
Prostate Cancer
Interventions
diagnostic laboratory biomarker analysis, flow cytometry, physiologic testing, computed tomography
Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

NCT00022412
View directory record Official record
Conditions
Prostate Cancer
Interventions
doxercalciferol, conventional surgery
Dietary Supplement · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Selenium in Treating Patients With Prostate Cancer

NCT00752739
View directory record Official record
Conditions
Prostate Cancer
Interventions
selenium, placebo
Dietary Supplement · Other
Lead sponsor
University of Arizona
Other
Eligibility
Up to 85 Years · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Jul 23, 2026, 6:32 PM EDT
Active, not recruiting Not applicable Interventional

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

NCT04985565
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
Interventions
Dietary Intervention, Radical Prostatectomy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 23, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 23, 2026, 6:32 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT07667400
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
SX-682, DTX
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer

NCT00004178
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

NCT06235099
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
Copper Cu 64 PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
31
States / cities
Fullerton, California • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

NCT01420250
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Drug · Radiation · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 23, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

NCT03570476
View directory record Official record
Conditions
Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Olaparib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

NCT01083368
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, bevacizumab, polymorphism analysis, laboratory biomarker analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Cleveland, Ohio • Willoughby Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jul 23, 2026, 6:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 6:32 PM EDT
Recruiting Not applicable Interventional

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

NCT07468903
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Not applicable Interventional Results available

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

NCT02470910
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

NCT00450229
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
Interventions
diindolylmethane, placebo, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

NCT01261754
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc MIP 1404, 99mTc MIP 1405
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jul 23, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

NCT00071968
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jul 23, 2026, 6:32 PM EDT